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Oxidative phosphorylation inducers
fight pathological angiogenesis
M.Pilar Bayona-Bafaluy1,2,3, pbayona@unizar.es, Olivia Esteban2,4, Javier Ascaso2,4, Julio Montoya1,2,3
and Eduardo Ruiz-Pesini1,2,3,5, eduruiz@unizar.es
Pathological mutations in subunits of the oxidative phosphorylation (OXPHOS) system, or inhibitors of
this biochemical pathway, increase the production of vascular endothelial growth factor (VEGF) and
pathological angiogenesis. In many angiogenesis-related diseases, such as retinal, rheumatoid diseases,
or cancer, OXPHOS dysfunction can be found. Thus, enhancing OXPHOS might be a promising
therapeutic approach for pathologic angiogenesis.
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Introduction
The neovascular form of age-related macular
degeneration (nAMD) is a disorder that affects
the macular region of the retina and causes
progressive loss of central vision. Age is the main
risk factor, with nearly all nAMD cases occurring
in patients over 60 years old. The disease is
characterized by choroidal neovascularization,
and intravitreal therapy with ranibizumab, an
inhibitor of all VEGFA isoforms, is highly effective
[1]. However, a meta-analysis of 1-year results
pointed out that a saturation effect of treatment
occurred following an optimal number of 6.8–
7.2 intravitreal ranibizumab injections per year
[2]. If this is the case, the increased injection
number might reflect refractory cases that re-
spond poorly to ranibizumab. In patients with
nAMD, the mitochondrial DNA (mtDNA) genetic
background or haplogroup also modifies the
response to intravitreal ranibizumab therapy [3].
At 4 months, in all haplogroups, best corrected
visual acuity and central foveal thickness (CFT)
values were higher and lower than basal values,
respectively. There were no differences amongPlease cite this article in press as: Bayona-Bafaluy, M.P. et a
1359-6446/ã 2019 Elsevier Ltd. All rights reserved.
https://doi.org/10.1016/j.drudis.2019.03.014 genetic backgrounds. However, at 12 months,
CFT values of patients from the HV and U
haplogroups remained lower than basal values,
whereas individuals from the JT haplogroup
showed similar CFT values to those before
treatment. Moreover, individuals from the U
haplogroup showed 12-month CFT values that
were significantly lower than those of JT hap-
logroup. However, individuals from the JT hap-
logroup received a higher mean number of
intravitreal injections (7.1) compared with the
other haplogroups. Therefore, other approaches
to treating nAMD should be looked for.
By contrast, mtDNA haplogroups result in
groups of phylogenetically related mtDNA
genotypes. Particular combinations of mtDNA
population polymorphisms define mtDNA
haplogroups. mtDNA only encodes OXPHOS
system subunits: seven from respiratory
complex I (CI); one from CIII; three from CIV;
and two from ATP synthase. It also encodes
RNAs required for their expression. The~80
remaining OXPHOS subunits are encoded
by nuclear DNA (nDNA). Thus, the mtDNAl.haplogroup-defining genetic variants might
affect OXPHOS function.
Therefore, evidence highlighting the associ-
ation between mtDNA haplogroups and the
clinical results of ranibizumab therapy in nAMD
could be the result of a relationship between
OXPHOS capacity and angiogenesis.
OXPHOS mutations and inhibitors
increase VEGF production and
pathological angiogenesis
nDNA mutations
Mutations in nDNA-encoded CII subunits result
in decreased CII activity, increased VEGF mRNA
expression, and stimulation of the angiogenic
pathway in paraganglioma and pheochromo-
cytoma tumors [4,5]. Similarly, mutations in the
nDNA-encoded CIII subunit UQCRB also de-
creased OXPHOS function and increased VEGF
mRNA and protein expression in UQCRB mutant
transfected human embryonic kidney HEK293
cells [6].
Furthermore, vascular proliferation is a
common feature of mitochondrial defects inwww.drugdiscoverytoday.com 1
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ystem of patients with Leigh syndrome (LS) [7].
he genetic basis of LS is diverse and mutations
ausing this disease have been defined in many
DNA genes mainly associated with OXPHOS
nction, including CI (NDUFV1, 2; NDUFS1, 2, 3,
, 7, 8; and NDUFA1, 2, 9, 10, 12), CIII (UQCRQ), and
IV (NDUFA4) genes [8]. Nevertheless, LS also
sults from mtDNA mutations [8].
tDNA mutations
uman SK-Hep1 hepatoma cells lacking mtDNA
ho0 cells) express more VEGF mRNA and pro-
in than parental cells with mtDNA, rho+ cells.
oreover, conditioned medium from these rho0
ells increased the formation of tube-like
tructures from human umbilical vein endo-
elial cells and new blood vessels in chorioal-
ntoic membrane assays [9]. Mice expressing a
utant mtDNA polymerase showed mtDNA
epletion, reduced OXPHOS enzyme activities,
nd increased expression of VEGF mRNA [10].
Transmitochondrial cell lines, cytoplasmic
ybrids, or cybrids can be used to confidently
nk a phenotype to mtDNA mutations. These
ells share nDNA and differ in their mtDNA. By
sing this model, it was shown that cybrids
btained from mouse Lewis lung carcinoma
ells, harboring a CI mutation and having an
XPHOS defect, showed increased VEGF mRNA
nd protein levels and higher activity to induce
eoangiogenesis than those with no mtDNA
utation [11,12].
In patients with mitochondrial myopathies
ttributable to heteroplasmic mtDNA mutations,
 which mutated and wild-type mtDNA are
resent, muscle capillary density was twice that
 sedentary healthy subjects and the capillary
rea was greatest in patients with the most
evere muscle OXPHOS defects. It was also
hown that, for each patient, capillary area
round muscle fiber segments with defective
XPHOS function was more than twice that
ompared with muscle fiber segments with
ore preserved OXPHOS function. Thus, lower
nd higher OXPHOS function likely mirror a
igher and lower percentage of mtDNA path-
logic mutations, respectively [13].
In terms of visual disorders, an optic disc
icroangiopathy has been described as a typical
phthalmoscopic feature in patients who are
symptomatic for, or have, acute Leber heredi-
ry optic neuropathy (LHON). LHON is an
herited form of vision loss that is caused by
tinal ganglion cell dysfunction, mainly result-
g from pathologic mutations in mtDNA genes.
terestingly, mtDNA J haplogroup increases the
sk for LHON [14]. It was recently reported that,Please cite this article in press as: Bayona-Bafaluy, M.P. et 
 www.drugdiscoverytoday.comwhen peripapillary capillary vessel density was
normalized by retinal nerve fiber layer thickness,
the vascular network in the temporal sectors
was increased in unaffected patients with LHON
mutation. This suggests that the metabolic
consequences of retinal ganglion cell mito-
chondrial impairment result in a compensatory
vascular response, primarily affecting the area of
the papillomacular bundle [15].
OXPHOS inhibitors
Given these earlier observations, mitochondrial
dysfunction because of OXPHOS inhibitors
might elevate VEGF levels. Supporting this as-
sertion, in vitro pretreatment of human adipose-
derived stroma cells with CI or CIII inhibitors
(rotenone or antimycin, respectively) increased
VEGF secretion. Following their injection into
mice, the angiographic score and capillary
density also increased [16]. Another CI inhibitor
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine),
frequently used to model Parkinson disease, also
increased the number of VEGF-expressing
neurons and of blood vessels in the substantia
nigra of parkinsonian-rendered monkeys [17].
Treatment of human brain microvascular peri-
cytes with the CIV inhibitor sodium cyanide also
resulted in increased expression of VEGF [18].
Hydrogen sulfide, another CIV inhibitor, also has
proangiogenic effects [19]. The ATP synthase
inhibitor oligomycin increased VEGF protein
production in the human U-937 monocytic cell
line [20]. Likewise, 4-hydroxy-2-nonenal in-
creased mtDNA point mutations and reduced
CIII and CIV activity and oxygen consumption in
primary rheumatoid arthritis synovial fibroblasts
(RASF). This compound also increased RASF
VEGF immunofluorescence staining and VEGF
secretion. The number of tube-like structures
produced by human umbilical vein endothelial
cells was also increased by 4-hydroxy-2-none-
nal-treated RASF-conditioned medium [21].
Opposite observations
The earlier results suggest that OXPHOS defi-
ciency promotes pathological angiogenesis.
However, some results point in an opposite
direction. For example, inhibition of the nDNA-
encoded mitochondrial tryptophanyl-tRNA
synthetase in endothelial cells reduced angio-
genesis [22]; mutations in mtDNA-encoded
tRNA genes decreased VEGF levels and angio-
genesis [23,24]; inhibitors of mitochondrial
translation (tigecycline and doxycycline) re-
duced neovascularization [25,26]; and rotenone
and antimycin decreased VEGF production and
angiogenesis in human ovarian cancer OVCAR-3,
liver cancer HepG2 or mouse sarcoma-180 cellsal.[27,28]. Therefore, the relationship between
pathological angiogenesis and OXPHOS func-
tion is complex and more studies are required
for it to be fully understood.
Pathological angiogenesis is a feature of
many OXPHOS disorders
Pathological angiogenesis can be observed in a
range of disorders [29,30], such as ocular [31,32],
rheumatic diseases [33,34], or cancer [35,36].
This might share a common early cause in these
disorders. Thus, hypoxia appears to be the
stimulus for retinal [37,38], synovial [39,40], or
tumoral [41] angiogenesis. An essential adap-
tation to sustained hypoxia is the repression of
mitochondrial respiration [42–44]. Angiogenesis
frequently occurs in cancer, but nonangiogenic
tumours can grow without triggering new vessel
formation. Energy metabolism varies between
angiogenic and nonangiogenic tumours. The
latter show higher expression of proteins asso-
ciated with OXPHOS and mitochondrial bio-
genesis [45,46]. It might be that OXPHOS
dysfunction explains why pathological angio-
genesis occurs in these diseases.
Primary OXPHOS disorders, such as those
mentioned earlier, are not common [47]. How-
ever, many prevalent diseases are secondary
OXPHOS disorders [48]. Mitochondrial altera-
tions are often found in many of these angio-
genesis-related disorders. Thus, retinal pigment
epithelium from patients with AMD shows a
decrease in the number and area of mito-
chondria compared with age-matched controls
[49]. Mitochondrial oxygen consumption was
significantly lower in retinal pigment epithelium
from donors with AMD [50]. Mitochondrial
number and COXIV protein levels were dimin-
ished in high glucose-cultured bovine retina
endothelial cells. Moreover, in diabetic mouse
retina or retina from patients with proliferative
diabetic retinopathy, mtDNA was damaged and
mtDNA copy number, mtDNA-encoded genes,
mRNA amount, nDNA-encoded COXIV protein
levels, and citrate synthase activity were all
decreased [51]. In rheumatoid arthritis (RA),
synovial fibroblasts undergo a shift in ATP
generation from OXPHOS to glycolysis, which
could be an adaptation to the joint microenvi-
ronment, similar to that seen in tumor cells
[40,52,53]. Regarding cancer, mtDNA mutations
are common and tumor growth is promoted by
mtDNA mutations affecting OXPHOS function
[54–56].
If an important OXPHOS dysfunction can in-
crease pathological angiogenesis, then mtDNA
haplogroup-associated OXPHOS variation might
be a susceptibility and/or resistance factor for
Q5
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For example, as discussed earlier, OXPHOS ca-
pability was lower in cybrids from the JT hap-
logroup [57] and OXPHOS electron transport
rate was higher in cybrids from the U hap-
logroup [58]. Interestingly, the JT haplogroup
appears to be a susceptibility factor for nAMD
[59], and individuals from this haplogroup
showed a worse response to nAMD intravitreal
ranibizumab therapy [3]. By contrast, the U
haplogroup appears to be a resistance factor for
proliferative diabetic retinopathy [60,61], and
individuals from this haplogroup showed a
better response to nAMD intravitreal ranibizu-
mab therapy [3]. In RA, radiographic erosions
were significantly associated with the JT hap-
logroup [62] and, in early RA, an association was
reported between erosions and increased intra-
articular blood flow [63]. The mtDNA hap-
logroup has also been related to cancer risk [64–
66].
Thus, these results suggest that OXPHOS
function is impaired, and should be analyzed, in
other angiogenesis-related disorders [29].
Enhancing OXPHOS function would
reduce pathological angiogenesis
If mechanisms underlying angiogenesis-de-
pendent diseases are related, therapies for one
disease might be helpful for others. OXPHOS
dysfunction appears to contribute to these pa-
thologies. Therefore, interventions to improve
OXPHOS function would have widespread clin-
ical applications. It was recently reported that
the loss of b-adrenergic receptor signaling leads
to inhibition of angiogenesis through en-
hancement of endothelial OXPHOS [67]. Also,
the loss of the glycolytic isoenzyme pyruvate
kinase M2 increased oxygen consumption rate
and led to angiogenic sprouting defects [68].
Two main types of antiangiogenic drug have
been developed: (i) monoclonal antibodies, or
related molecules, targeting either VEGF or the
extracellular domain of its receptor; and (ii)
tyrosine-kinase inhibitors (TKI), targeting the
intracellular kinase domains of VEGF, or other
tyrosine kinase receptors. It was recently shown
that monoclonal antibody-related molecules
increased the respiration rate in human adult
retinal pigment epithelial-19 (ARPE-19) cells [69].
Moreover, it was also shown that tumor me-
tabolism was reprogrammed in response to TKI,
with increased mitochondrial metabolism. Thus,
TKI-treated tumor tissue had intense CII staining
and its respiratory capacity was higher than that
of control-treated tumor tissue [70].
Several agents have already been proposed
that, by acting on different cell targets, increasePlease cite this article in press as: Bayona-Bafaluy, M.P. et amitochondrial biogenesis [14]. Some of these
compounds also appear to be beneficial for
angiogenesis-related diseases. For example,caf-
feine [71,72]; polyphenols, such as curcumin,
epigallocatechin gallate, quercetin, and resver-
atrol [73–76]; thiazolidinediones, such as rosi-
glitazone [77,78]; valproic acid [79,80]; D9-
tetrahydrocannabinol [81,82]; and v3-polyun-
saturated fatty acids, such as docosahexaenoic
or eicosapentaenoic acids [83]. These com-
pounds could be used, along with other anti-
angiogenic drugs, as adjuvants for either all
patients with angiogenesis-related diseases or
those belonging to a particular mtDNA hap-
logroup with a high genetic risk.
Concluding remarks
This retrospective analysis reveals a previously
unrecognized pattern, that OXPHOS dysfunction
might be an etiological factor for pathological
angiogenesis. These observations lead to a new
hypothesis whereby OXPHOS inducers would be
interesting candidate drugs for the treatment of
diseases involving OXPHOS dysfunction. Nev-
ertheless, angiogenesis-related diseases also
include those in which angiogenesis is ham-
pered [29]. In such cases, OXPHOS inhibitors
might act as proangiogenic drugs.
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